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The gene SASH1 (SAM- and SH3-domain containing 1) has originally been identified as a candidate tumour suppressor gene in breast
cancer. SASH1 is a member of the SH3-domain containing expressed in lymphocytes (SLY1) gene family that encodes signal adapter
proteins composed of several protein–protein interaction domains. The other members of this family are expressed mainly in
haematopoietic cells, whereas SASH1 shows ubiquitous expression. We have used quantitative real-time PCR to investigate the
expression of SASH1 in tissue samples from 113 patients with colon carcinoma, and compared the expression with 15 normal colon
tissue samples. Moreover, nine benign adenomas and 10 liver metastases were analysed. Expression levels of SASH1 were strongly
and significantly reduced in colon cancer of UICC stage II, III, and IV, as well as in liver metastases. Moreover, SASH1 was also found to
be downregulated on protein levels by immunoblot analysis. However, SASH1 expression was not significantly deregulated in
precancerous adenomas and in earlier stage lesions (UICC I). Overall, 48 out of 113 primary colon tumours showed SASH1
expression that was at least 10-fold lower than the levels found in normal colon tissue. Downregulation of SASH1 expression was
correlated with the formation of metachronous distant metastasis, and multivariate analysis identified SASH1 downregulation as an
independent negative prognostic parameter for patient survival. This study demonstrates for the first time that expression of a
member of the SLY1-gene family has prognostic significance in human cancer.
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Many of the molecular changes associated with tumour formation
have been defined for colorectal cancer, owing to the high
frequency of the disease and the relatively simple access to
virtually all tumour stages by endoscopy (Fearon and Vogelstein,
1990; Kinzler and Vogelstein, 1996). However, many more genes,
some still uncharacterised, are likely to be involved in tumour
progression and metastasis formation. We have focused on the
gene SASH1 (SAM- and SH3-domain containing 1) that has
previously been described as candidate tumour suppressor gene in
breast cancer (Zeller et al, 2003). SASH1 was mapped to
chromosome 6q24.3, loss of heterozygosity (LOH) of this region
(occurring in 30% of primary breast cancers) was associated with
poor survival and increase in tumour size. Moreover, a strong
reduction of SASH1 expression was observed in the majority of
breast tumours when compared to normal mammary epithelia
(Zeller et al, 2003). Loss of chromosomal region 6q24–25 has also
been detected in a study on primary colorectal tumours, and was
specifically associated with invasive tumours extending to the
serosal fat (Alcock et al, 2003). However, the predictive capacity of
SASH1 deregulation in human cancer has not been determined
previously. The domain structure and strong sequence similarities
places SASH1 in the SH3-domain containing expressed in
lymphocytes (SLY1) family of signal adapter proteins, which was
first identified in haematopoietic cells (Beer et al, 2001), and
comprises in addition the proteins SLY1, and HACS1 (or SLY2,
NASH1). SLY1 is involved in regulation of the adaptive immune
system (Beer et al, 2001, 2005). HACS1 (or NASH1) is expressed in
mast cells, and was reported to be differentially expressed in
malignant haematopoietic cells (Claudio et al, 2001; Uchida et al,
2001; Zhu et al, 2004). Whereas the expression of SLY1 and HACS1
seems to be restricted to haematopoietic cells, SASH1 shows
ubiquitous expression in human tissue (Zeller et al, 2003). Here,
we provide the first evidence that downregulation of SASH1
constitutes an independent prognostic parameter in colon cancer.
PATIENTS, MATERIALS AND METHODS
Patients
Informed, written consent regarding the use of the tissue samples
was obtained from each subject before the study. Tissue samples
were obtained from 113 patients admitted to our Department of
Surgery with the diagnosis colon carcinoma. The group consisted
of 69 male and 44 female patients, mean age was 64 years. None of
the patients suffered of a known second neoplastic disease; only
complete resected tumours (R0) were included in the study.
Median survival after surgery was 91 months (range: 44–131
months). During this period, 38 patients died owing to tumour-
related causes. Disease recurred in 15 patients, 34 patients
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sdeveloped metachronous distant metastases, and 23 patients
showed disease progression. Tumour localisation was: ascending
colon (41 cases), transverse colon (12 cases), descending colon (18
cases) and sigmoid colon (42 cases). Tumour grading was: G1
(three cases), G2 (74 cases), G3 (33 cases) and G4 (three cases).
Tumour stages according UICC classification were: stage I (12
cases), stage II (45 cases), stage III (23 cases), and stage IV (33
cases). Sixty-five patients had no adjuvant treatment, and 48
patients received systemic chemotherapy. As a control, we
examined normal colon tissue (15 patients), benign colonic
adenomas (nine patients), and liver metastases from 10 patients.
Samples were frozen in liquid nitrogen immediately after surgery
and stored at  801C.
RNA Isolation from cell lines and tissue samples
To establish and validate the quantification of SASH1 expression
the following human cell lines were used: HEK293 (embryonic
kidney epithelial cells), HeLa (cervical carcinoma), SKOV-3
(ovarian adenocarcinoma), CaCo2 (grade II colorectal adeno-
carcinoma), HT29 (grade I colorectal adenocarcinoma), Jurkat
(T-lymphocyte from acute T-cell leukaemia), and Ramos
(B-lymphocyte from Burkitt’s lymphoma). For RNA isolation
from tissue, we used 40 sections of 12mm thickness (surface
approximately, 1–2cm
2). Immunochemistry (haematoxylin (H)
and eosin (E) staining) was performed on each first and last
section to ensure tumour content above 70%. Accordingly, frozen
sections from resected normal colon tissue (as certified by an
experienced pathologist) were subjected to the same protocol. RNA
was isolated using the RNeasy Kit (Qiagen, Hilden, Germany),
quantified, and checked for degradation on a denaturing
formaldehyde–agarose gel. cDNA preparation was performed
according to standard procedures, using SuperscriptII H-Reverse
Transcriptase (Invitrogen, Karlsruhe, Germany) and oligo-dT
primers (pd(N)6; Roche Alameda, CA, USA).
Quantitative real-time PCR
Expression of SASH1 and SLY1 transcripts was determined by real-
time reverse transcriptase–polymerase chain reaction (RT—PCR)
using the ABI PRISM 7300 sequence detection system (Applied
Biosystems, Foster City, CA, USA) with the dye SYBRGreen I.
Expression of the housekeeping gene HPRT was used as internal
reference.
K HPRT-F: 50-GCT TTC CTT GGT CAG GCA GTA TAA T-30
K HPRT-R: 50-AAG GGC ATA TCC TAC AAC AAA CTT G-30
K SASH1-F: 50- CGG GAA AGC GTC AAG TCG GA-30
K SASH1-R: 50- ATC TCC TTT CTT GAG CTT GAG-30
K SLY1-F: 50- TCC AGC AGC TTC AAG GAT TT-30
K SLY1-R: 50- CAT CTT GCC CAT CTT CCT GT-30
Statistical analysis
Analyses were performed using SPSS version 9.0 (SPSS, Munich,
Germany). Statistical significance was defined as Pp0.05. As data
sets were too small to assume normal distribution, nonparametric
tests were used. The results were analysed with the Kruskal–Wallis
test or Mann–Whitney U-test to check for significant differences
between individual groups. Expression of SASH1 was assessed in
terms of survival by the Cox proportional hazards model using
univariate and multivariate analysis. Significance was tested by w
2
analysis.
Preparation of protein lysates
Resected tumours and normal colon tissue samples (as certified by
an experienced pathologist) were snap-frozen in liquid nitrogen in
lactate buffered Ringer’s solution, and stored at  801C. Tissue
samples were thawn quickly and homogenised in pre-cooled
Dounce homogenisers in TBST buffer (20mM Tris/HCl, pH 8.5,
150mM NaCl, 1% Triton X-100). After homogenisation, samples
were extracted overnight at 41C, and subsequently centrifuged for
1h, 41C, at 100000g in an ultracentrifuge (Beckman, Krefeld,
Germany). Supernatants were collected, frozen in liquid nitrogen,
and stored at  801C. Protein concentration was determined with a
Bradford Assay (Biorad, Munich, Germany).
Immunoblotting and antibodies
Equal amounts (40mg) of protein lysates were boiled in Laemmli
buffer for 5min, separated on 10% polyacrylamide gels, and
subjected to immunoblotting according to standard procedures
(Towbin et al, 1979). Mouse monoclonal anti-b-tubulin antibody
(Oncogene Research Products, Darmstadt, Germany) was used as
loading control. A polyclonal rabbit anti-serum was generated by
immunisation with two specific peptides corresponding to amino-
terminal sequences of murine SASH1, and the serum was further
affinity-purified with the peptides. A detailed description of the
antiserum will be subject of a future publication. Briefly, the
antiserum was used at 1:2000 dilution on the immunoblots (at
41C, overnight), recognising a specific band of an apparent
molecular weight of 180kDa in normal human colon lysates.
Secondary antibodies were horseradish peroxidase-conjugated
goat anti-mouse IgG and goat anti-rabbit IgG (Jackson Immuno-
research, West Grove, PA, USA), visualised with an enhanced
chemiluminescence substrate detection kit (Pierce, Rockford, IL,
USA).
RESULTS
We have first tested normal human tissues and cell lines by qRT–
PCR for the expression of SASH1 and its homolog SLY1. SASH1
expression was detected in colon, liver and peripheral lymph
nodes, and in reduced amounts as compared to normal colon in
various cell lines of epithelial origin (HEK293, SKOV-3, CaCo2)
(Figure 1A). Interestingly, expression in HT29 cells (corresponding
to well-differentiated colorectal adenocarcinoma) was two-fold
higher than in normal colon. SASH1 expression was very low to
undetectable in lymphoblastoid cells (Jurkat and Ramos cells) and
HeLa cells. The expression patterns of SASH1 and its homologue
SLY1 were found to be mutually exclusive, as SLY1 was expressed
in the lymphoblastoid cells, but undetectable in epithelial cells.
Correspondingly, SLY1 showed highest expression in lymph
nodes, and about 10-fold lower expression in colon. It has been
reported that protein kinase C (PKC) is a regulator of SASH1
expression (Lindvall et al, 2005). However, we could not observe
any difference in expression of SASH1 upon stimulation of PKC
with phorbol 12-myristate 13-acetate (PMA)/ionomycin in all cell
lines tested (not shown).
Next, we analysed primary colon carcinomas from 113 patients
and compared the expression with 15 normal colon samples
(Figure 1). In addition, nine precancerous lesions (adenoma) were
analysed. SASH1 was significantly downregulated in tumour stages
UICC II, III and IV, but not in adenomas or UICC stage I cancers
(Figure 1B). Forty-two per cent of all carcinomas (48 out of 113
samples) showed SASH1 expression that was 10-fold lower in
comparison to normal colon tissue. Of note, we detected high
levels of expression (45-fold of the median expression in normal
colon) in five tumour samples (4%), and in three normal colon
tissues (23%). However, SASH1 expression was not significantly
correlated to the anatomical tumour site.
We then compared matched normal colon tissue, primary
tumour and colorectal liver metastasis from five individual
patients (Figure 2). In all cases, the expression of SASH1 was
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ssignificantly reduced in the liver metastasis as compared to normal
colon tissue. In three cases, SASH1 was already downregulated in
the primary tumour, and in two patients, the SASH1 mRNA level of
the liver metastasis was significantly lower than that of the
matched primary tumour (Po0.01). As the expression levels of
SASH1 in normal human liver were not well established so far, we
have compared liver metastases to normal liver tissue from nine
patients. We could confirm that SASH1 was significantly down-
regulated in the metastatic tissue also in comparison to the normal
surrounding liver tissue.
The observed downregulation of SASH1 expression may not
necessarily be found on protein levels. Therefore, we have
generated a polyclonal rabbit anti-serum that specifically recog-
nises a peptide epitope of SASH1. In a restricted subset of patient
samples (n¼10), where sufficient material (450mg) from both
normal and tumour tissue from the same patient was available for
protein extraction, we have tested expression by immunoblotting.
SASH1 signals were visible at 180kDa (Figure 3, arrowhead),
somewhat exceeding the predicted molecular weight of 140kDa.
Downregulation of SASH1 protein was detectable in eight out of 10
tested tumours. Figure 3 shows representative examples: tumours
from patients #1 and #2 show strong downregulation of SASH1,
whereas tumour #3 has an equal expression of SASH1 in normal
and cancer tissue. Interestingly, a prominent second band with
higher electrophoretic mobility (about 110kDa) was detected in
tumour lysates with the anti-SASH1 anti-serum, especially strong
in normal tissue from patient #2 (Figure 3, arrow). This lower band
may correspond to a degradation product, or to a splice variant of
SASH1. After preincubation of the immunoblot with a 10-fold
molar excess of the peptides against which the antiserum was
generated, both bands were no longer visible, demonstrating the
specificity of the immunoreactive bands (not shown).
SASH1 transcript expression was not correlated with disease
recurrence, but there was a significant correlation of SASH1
expression with metastasis formation: SASH1 downregulation was
correlated with the development of metachronous metastasis,
defined as metastases occurring more than 6 months after
resection of the primary tumour (P¼0.014, Mann–Whitney
U-test). SASH1 downregulation was also associated with the
progression of synchronous metastasis (P¼0.046, Kruskal–Wallis
H-test). The group of 113 patients was then statistically evaluated
by multivariate regression analysis for overall survival using the
following factors: age, sex, disease recurrence, pT and nodal status
(pN) status, tumour grading, and SASH1 expression (Table 1).
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Figure 1 (A) Relative expression of SASH1 and SLY1 determined by
qRT–PCR in normal human tissue (n¼3 specimen) and cell lines,
normalised to the expression in colon. Means7s.d. for three independent
experiments. Asterisk: no expression detectable. (B) Relative SASH1
expression in normal colon (n¼15), benign adenomas (n¼9), and primary
colon tumours from stages UICC stage I (n¼12), stage II (n¼45), stage III
(n¼23), and stage IV (n¼33). Moreover, liver metastases (n¼10) and
normal liver tissue (n¼9) not shown was analysed. SASH1 expression was
significantly different from normal tissue in: UICC stage II (P¼0.031), UICC
stage III (P¼0.047), UICC stage IV (P¼0.043), and in liver metastases
(P¼0.030). The bar indicates median expression for each group.
Expression was normalised to the median expression of all normal colon
samples.
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Figure 2 Relative expression of SASH1 in matched normal tissue,
primary colon tumours and liver metastasis from five patients, normalised
to the median expression of all normal colon samples. Mean7s.d. is
indicated for three replicate measurements. Note: Normal colon was not
available for patient #4.
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Figure 3 SASH1 protein expression in tumour (marked ‘T’) and
matched normal tissue (marked ‘N’) from three representative patients.
The SASH1 signal has an apparent molecular weight of 180kDa
(arrowhead). SASH1 expression was lower in tumour than in correspond-
ing normal tissue in eight out of 10 tested patients, as seen in patients #1
and #2. In case #3, SASH1 expression was unchanged in the tumour as
compared to normal colon. Note the presence of a prominent additional
band with higher electrophoretic mobility, which is also reduced in tumours
(arrow). Tubulin staining as loading control indicated in the lower panel.
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colon) independently predicted survival in this multivariate
analysis using the Cox proportional hazard model, with a relative
risk of 2.9 (P¼0.005). This analysis also retained known
independent predictors for survival, such as disease recurrence,
pN, and tumour grading, whereas age and sex were not retained.
The pT status was retained in univariate, but not in multivariate
analysis as independent parameter.
DISCUSSION
A tremendous amount of information has been achieved regarding
the molecular and cellular changes associated with colon cancer.
However, the overall survival rate for this disease has not
substantially improved over the last 20 years (Parker et al, 1997),
and patient prognosis still relies mainly on the penetration depth
of the tumour and the spreading of the disease to other organs. The
identification of new genes functionally involved in tumour
development and progression may help to find alternative
approaches for prognostic and diagnostic evaluation. Our study
focuses on SASH1, a new candidate tumour suppressor gene of the
SLY1 family of signal adapter proteins. We have observed broad
expression of SASH1 in various normal tissues and epithelial cell
lines, with the exception of lymphoblastoid cells. The observed
expression pattern of SASH1 was complementary to that of its
homologue SLY1.
Interestingly, SASH1 expression was significantly downregulated
in invasive and metastasised tumours. The downregulation of
SASH1 expression was validated and reproduced independently by
immunoblot analysis. SASH1 expression was not reduced in
adenomas and locally restricted, low-stage tumours (UICC I).
Therefore, it is tempting to speculate that SASH1 does not play a
role in the early phases of tumour initiation, but is rather related to
processes such as tumour invasion in the surrounding tissue, and
dissemination of tumour cells to distant organs. Indeed, SASH1
expression was clearly downregulated in liver metastasis, and the
expression levels in the metastases were equal to or lower than the
expression in the primary tumour from the same patient.
Statistical analysis revealed that downregulation of SASH1 in the
primary tumour correlated with the formation of metachronous,
postoperative metastasis, and with the progression of synchronous
metastases. Moreover, SASH1 downregulation was retained as an
independent negative prognostic factor for patient survival by
multivariate analysis.
Currently, the molecular mechanisms that regulate SASH1
expression are unknown. Stimulation of PKC in vitro was reported
to reduce SASH1 expression in primary B-lymphocytes (Lindvall
et al, 2005). Interestingly, PKC may play a role in colorectal cancer
formation (Zhang et al, 2004), and the homologue SLY1 is
regulated by PKC (Beer et al, 2005). However, we did not detect
any regulation of SASH1 expression by PMA/ionomycin stimula-
tion in vitro in various cell lines (HeLa, HEK293, HT29, Ramos).
Alternatively, the downregulation of SASH1 in tumours may be
explained by genetic mechanisms such as LOH or point mutations.
Indeed, frequent LOH at the SASH1 genomic locus 6q24–25 has
been reported in primary breast cancer, and also in one study in
primary colorectal tumours, with specific association with tumour
invasion to the serosal fat (Alcock et al, 2003; Zeller et al, 2003).
However, despite extensive sequencing efforts, Zeller and co-
workers have not been able to demonstrate invalidating mutations
in the second allele that would explain the lack of expression of
SASH1 in breast cancer (Zeller et al, 2003). Thus, epigenetic
mechanisms such as promoter hypermethylation may underlie the
observed downregulation of SASH1 expression.
In the patient collective, a subgroup of tumours displayed
normal or elevated levels of SASH1. This might be explained by the
different routes that lead to colorectal cancer. Sporadic cancers of
the colon are characterised by different forms of genetic instability,
which can manifest themselves in either chromosomal instability,
or, less frequently, in microsatellite instability (MSI). Interestingly,
SASH1 expression was normal in a tumour from a patient
diagnosed with hereditary nonpolyposis colorectal cancer
(HNPCC) syndrome and MSI-high status (not shown). Even
though sporadic MSI-high colon cancer differs from the rare
hereditary forms (Jass, 2004), it is tempting to speculate that there
may be a connection between normal SASH1 expression in
tumours and high MSI levels. However, the tumour samples in
this study were not generally characterised for their MSI levels.
Therefore, further investigations are necessary to clarify this
hypothetical correlation between MSI status and the expression of
the tumour suppressor SASH1.
The functional consequences of downregulated SASH1 expres-
sion are still unclear. The SASH1 gene encodes a large protein of
1230 amino acids that contains two SAM (sterile a-module)
domains, and one SH3-domain (Src homology domain 3). SH3
domains bind to proline-rich motifs in proteins (Pawson, 1995),
SAM domains are able to self-associate or to interact with other
protein domains (Kim et al, 2001, 2002). Both domains are
frequently found in signal adapter proteins or scaffolding factors.
Thus, the function of SASH1 may lie in the formation of
multiprotein signalling complexes that regulate cell survival,
proliferation, or migration. In conclusion, we have demonstrated
that downregulation of SASH1 expression in colon cancer is
associated with metastasis and bad prognosis.
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